-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – evolocumab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry evolocumab Drug Details Evolocumab (AMG-145, Repatha) is a monoclonal antibody acts as lipid modifying...
-
Product Insights
3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA),...